Cargando…

Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study

BACKGROUND: Drug resistance is a major problem in the treatment of tuberculosis (TB). An estimate of drug resistance is extremely important in the epidemiology and control of TB. However, an assessment of the magnitude of drug resistance in TB is not very well described globally and data remains sca...

Descripción completa

Detalles Bibliográficos
Autores principales: Menon, Sarala, Dharmshale, Sujata, Chande, Chhaya, Gohil, Aruna, Lilani, Sunil, Mohammad, Salim, Joshi, Ameeta, Chowdhary, Abhay, Bharadwaj, Renu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424860/
https://www.ncbi.nlm.nih.gov/pubmed/22919160
http://dx.doi.org/10.4103/0970-2113.99104
_version_ 1782241274852540416
author Menon, Sarala
Dharmshale, Sujata
Chande, Chhaya
Gohil, Aruna
Lilani, Sunil
Mohammad, Salim
Joshi, Ameeta
Chowdhary, Abhay
Bharadwaj, Renu
author_facet Menon, Sarala
Dharmshale, Sujata
Chande, Chhaya
Gohil, Aruna
Lilani, Sunil
Mohammad, Salim
Joshi, Ameeta
Chowdhary, Abhay
Bharadwaj, Renu
author_sort Menon, Sarala
collection PubMed
description BACKGROUND: Drug resistance is a major problem in the treatment of tuberculosis (TB). An estimate of drug resistance is extremely important in the epidemiology and control of TB. However, an assessment of the magnitude of drug resistance in TB is not very well described globally and data remains scantier for India. In view of this, we reviewed our data over last five years. MATERIALS AND METHODS: Six hundred and seventy-three Mycobacterium tuberculosis isolates were subjected to drug susceptibility against primary anti-tuberculosis drugs by economic variant proportion method. All isolates resistant to isoniazid and rifampicin were taken as multi-drug resistant (MDR). RESULTS: Out of the 673 strains tested, 95 (14.11%) showed monoresistance, 365 (54.23%) strains were found to be resistant to more than one drug. A total of 118 (17.53%) strains were found to be resistant to all the four drugs tested. MDR was seen with 320 (47.54%) isolates. This study observed maximum resistance with rifampicin (74.4%) followed by streptomycin (70.0%), isoniazid (53.2%), and ethambutol (21.7%). CONCLUSION: While this information may not reflect true prevalence of drug resistance in the region, this may help in further planning long term surveillance studies to know the trend of drug resistance in this area.
format Online
Article
Text
id pubmed-3424860
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-34248602012-08-23 Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study Menon, Sarala Dharmshale, Sujata Chande, Chhaya Gohil, Aruna Lilani, Sunil Mohammad, Salim Joshi, Ameeta Chowdhary, Abhay Bharadwaj, Renu Lung India Original Article BACKGROUND: Drug resistance is a major problem in the treatment of tuberculosis (TB). An estimate of drug resistance is extremely important in the epidemiology and control of TB. However, an assessment of the magnitude of drug resistance in TB is not very well described globally and data remains scantier for India. In view of this, we reviewed our data over last five years. MATERIALS AND METHODS: Six hundred and seventy-three Mycobacterium tuberculosis isolates were subjected to drug susceptibility against primary anti-tuberculosis drugs by economic variant proportion method. All isolates resistant to isoniazid and rifampicin were taken as multi-drug resistant (MDR). RESULTS: Out of the 673 strains tested, 95 (14.11%) showed monoresistance, 365 (54.23%) strains were found to be resistant to more than one drug. A total of 118 (17.53%) strains were found to be resistant to all the four drugs tested. MDR was seen with 320 (47.54%) isolates. This study observed maximum resistance with rifampicin (74.4%) followed by streptomycin (70.0%), isoniazid (53.2%), and ethambutol (21.7%). CONCLUSION: While this information may not reflect true prevalence of drug resistance in the region, this may help in further planning long term surveillance studies to know the trend of drug resistance in this area. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3424860/ /pubmed/22919160 http://dx.doi.org/10.4103/0970-2113.99104 Text en Copyright: © Lung India http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Menon, Sarala
Dharmshale, Sujata
Chande, Chhaya
Gohil, Aruna
Lilani, Sunil
Mohammad, Salim
Joshi, Ameeta
Chowdhary, Abhay
Bharadwaj, Renu
Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study
title Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study
title_full Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study
title_fullStr Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study
title_full_unstemmed Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study
title_short Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study
title_sort drug resistance profiles of mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: a five years study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424860/
https://www.ncbi.nlm.nih.gov/pubmed/22919160
http://dx.doi.org/10.4103/0970-2113.99104
work_keys_str_mv AT menonsarala drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy
AT dharmshalesujata drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy
AT chandechhaya drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy
AT gohilaruna drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy
AT lilanisunil drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy
AT mohammadsalim drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy
AT joshiameeta drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy
AT chowdharyabhay drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy
AT bharadwajrenu drugresistanceprofilesofmycobacteriumtuberculosisisolatestofirstlineantituberculousdrugsafiveyearsstudy